Pharmaceutical Product Development and NeoGenomics have formed a strategic alliance to provide global pathology and molecular testing solutions
Pharmaceutical Product Development (PPD) and NeoGenomics Laboratories are forming a strategic alliance to provide a seamless and fully integrated global pathology and molecular testing solution for PPD’s pharmaceutical and biotech clients.
As part of the collaboration, NeoGenomics, a provider of cancer-focused genetic testing services, will provide a wide range of lab testing services to support PPD Laboratories’ oncology clinical trial activities in the US, Europe and Asia.
“NeoGenomics has world-class scientific talent, significant oncology trial experience and a broad geographic presence that will allow us to further enhance our global laboratory services for oncology trials,” said Dr Christopher Fikry, executive VP of PPD Laboratories.
Operationally, the collaboration will leverage NeoGenomics sites in the US and Europe, and both companies expect to jointly invest in PPD’s existing labs in China and Singapore.
The companies will provide an integrated global IT solution, leveraging PPD’s Preclarus system to offer real-time visibility and analytics for informed decision-making.
Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers the industry a set of lab services spanning bioanalytical, biomarkers, central lab, GMP and vaccine sciences.
The new collaboration will focus on centralised pathology review, as well as specialty lab services, including flow cytometry, fluorescence in situ hybridisation (FISH), immunohistochemistry (IHC), cytogenetics, molecular assays, next-generation sequencing and MultiOmyx, NeoGenomics’ proprietary, multi-omics multiplexing methodology.
Together, the companies also will provide clients a comprehensive companion diagnostics offering from biomarker discovery through regulatory approval and commercialisation. Additionally, the teams are committed to leveraging their combined data assets to find more efficient methods of identifying appropriate patients for oncology trials.
“We are pleased to be joining PPD in this important strategic alliance and look forward to collaborating with the many scientific professionals on their team,” said Douglas VanOort, chairman and CEO of NeoGenomics.
“Our company is committed to saving lives by improving patient care through communication, accuracy, reliability and efficiency. That commitment aligns closely with PPD’s mission and purpose to help its customers deliver life-changing therapies that improve health.”
According to the cancer diagnostics and pharma services company, NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world to support physicians in the diagnosis and treatment of cancer and pharmaceutical clients in clinical trials and drug development.